Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

[Pharmacovigilance in children].

Autret-Leca E, Marchand MS, Cissoko H, Beau-Salinas F, Jonville-Béra AP.

Arch Pediatr. 2012 Aug;19(8):848-55. doi: 10.1016/j.arcped.2012.05.013. Epub 2012 Jun 27. French.

PMID:
22748689
[PubMed - indexed for MEDLINE]
2.

Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future.

Fabiano V, Mameli C, Zuccotti GV.

Expert Opin Drug Saf. 2012 Jan;11(1):95-105. doi: 10.1517/14740338.2011.584531. Epub 2011 May 9. Review.

PMID:
21548838
[PubMed - indexed for MEDLINE]
3.

Improving pediatric drug safety: need for more efficient clinical translation of pharmacovigilance knowledge.

Castro-Pastrana LI, Carleton BC.

J Popul Ther Clin Pharmacol. 2011;18:e76-88. Epub 2011 Mar 21.

PMID:
21467599
[PubMed - indexed for MEDLINE]
Free Article
4.

[Off-label use of psychotropic medications in pediatric wards: a prospective study].

Winterfeld U, Le Heuzey MF, Acquaviva E, Mouren MC, Brion F, Bourdon O.

Arch Pediatr. 2009 Sep;16(9):1252-60. doi: 10.1016/j.arcped.2009.06.012. Epub 2009 Jul 28. French.

PMID:
19640689
[PubMed - indexed for MEDLINE]
5.

Adverse drug reactions in children reported by means of the yellow card in Spain.

Morales-Olivas FJ, Martínez-Mir I, Ferrer JM, Rubio E, Palop V.

J Clin Epidemiol. 2000 Oct;53(10):1076-80.

PMID:
11027942
[PubMed - indexed for MEDLINE]
6.

The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients.

Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher W, Brune K, Hinz B.

Drug Saf. 2004;27(13):1059-67.

PMID:
15471510
[PubMed - indexed for MEDLINE]
7.

Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study.

Turner S, Nunn AJ, Fielding K, Choonara I.

Acta Paediatr. 1999 Sep;88(9):965-8.

PMID:
10519338
[PubMed - indexed for MEDLINE]
8.

Psychiatric adverse drug reactions reported during a 10-year period in the Swedish pediatric population.

Bygdell M, Brunlöf G, Wallerstedt SM, Kindblom JM.

Pharmacoepidemiol Drug Saf. 2012 Jan;21(1):79-86. doi: 10.1002/pds.2265. Epub 2011 Nov 10.

PMID:
22076661
[PubMed - indexed for MEDLINE]
9.

Pharmacovigilance: characteristics of the most widely used drugs in Bulgaria.

Getov I, Dimitrova Z.

Cent Eur J Public Health. 1999 Aug;7(3):133-6.

PMID:
10499144
[PubMed - indexed for MEDLINE]
10.

[Pharmacovigilance in pharmacy practice].

Duquet N.

J Pharm Belg. 2011 Dec;(4):97-103. French.

PMID:
22299235
[PubMed - indexed for MEDLINE]
11.

Adverse drug reactions and off-label drug use in paediatric outpatients.

Horen B, Montastruc JL, Lapeyre-Mestre M.

Br J Clin Pharmacol. 2002 Dec;54(6):665-70.

PMID:
12492616
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Perceived adverse drug reactions among non-institutionalized children and adolescents in Germany.

Knopf H, Du Y.

Br J Clin Pharmacol. 2010 Sep;70(3):409-17. doi: 10.1111/j.1365-2125.2010.03713.x.

PMID:
20716242
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.

Hartford CG, Petchel KS, Mickail H, Perez-Gutthann S, McHale M, Grana JM, Marquez P.

Drug Saf. 2006;29(8):657-73. Review.

PMID:
16872240
[PubMed - indexed for MEDLINE]
14.

Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment.

Henney HR 3rd, Chez M.

Paediatr Drugs. 2009;11(6):397-406. doi: 10.2165/11316090-000000000-00000.

PMID:
19877725
[PubMed - indexed for MEDLINE]
15.

Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database.

Strandell J, Wahlin S.

Eur J Clin Pharmacol. 2011 Jun;67(6):633-41. doi: 10.1007/s00228-010-0979-y. Epub 2011 Jan 21.

PMID:
21253716
[PubMed - indexed for MEDLINE]
16.

Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.

Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, Hazell L, Krska J, Lee AJ, McLernon DJ, Murphy E, Shakir S, Watson MC.

Health Technol Assess. 2011 May;15(20):1-234, iii-iv. doi: 10.3310/hta15200. Review.

PMID:
21545758
[PubMed - indexed for MEDLINE]
Free Article
17.

A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006.

Sommet A, Durrieu G, Lapeyre-Mestre M, Montastruc JL; Association of French PharmacoVigilance Centres.

Pharmacoepidemiol Drug Saf. 2012 Mar;21(3):285-8. doi: 10.1002/pds.2307. Epub 2011 Dec 8.

PMID:
22162094
[PubMed - indexed for MEDLINE]
18.

Adverse drug reactions in childhood: a review of prospective studies and safety alerts.

Clavenna A, Bonati M.

Arch Dis Child. 2009 Sep;94(9):724-8. doi: 10.1136/adc.2008.154377. Epub 2009 Jun 15. Review.

PMID:
19531524
[PubMed - indexed for MEDLINE]
19.

Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009.

Aldea A, García Sánchez-Colomer M, Fernández Quintana E, García Sáiz M.

Eur J Clin Pharmacol. 2012 Sep;68(9):1329-38. doi: 10.1007/s00228-012-1255-0. Epub 2012 Mar 14.

PMID:
22415248
[PubMed - indexed for MEDLINE]
20.

[Organization and results of drug vigilance in France].

Bégaud B, Chaslerie A, Haramburu F.

Rev Epidemiol Sante Publique. 1994;42(5):416-23. French.

PMID:
7973001
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk